CLEVELAND, Aug. 7, 2017 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) today announced financial results for the second
quarter and six months ended June 30,
2017.
Second Quarter 2017 Highlights:
- Received record quarterly new orders for MRIdian Linac Systems,
totaling $37.3 million, compared to
orders totaling $17.1 million in Q2
2016
- Total backlog grew to $182.1
million, as of June 30, 2017,
up from $100.7 million as of
June 30, 2016.
- In May, compelling early data for pancreatic cancer treatment
with MRIdian System was presented at ESTRO 36; presentations also
highlighted the speed and benefit of On-Table Adaptive Therapy with
MRIdian in routine clinical use
(http://www.viewray.com/estro_2017.htm)
- Raised $17.6 million from the
sale of 2.6 million shares of common stock through "at the market"
offerings
Recent Highlights:
- In July, announced the first patient treatments on the MRIdian
Linac at Henry Ford Hospital in Michigan
- In July, at the 2017 Annual Meeting of the American Association
of Physicists in Medicine (AAPM), 30 presentations highlighted
MRIdian's capabilities including on-table adaptive planning for
escalating dose while sparing healthy tissue and the first clinical
experience with MRIdian Linac.
"In the second quarter, we saw increased momentum following the
FDA clearance of the MRIdian Linac, highlighted by $37.3 million in new orders," said Chris A. Raanes, president and chief executive
officer of ViewRay. "Our commercial momentum is supported by a
growing body of compelling clinical data demonstrating the benefits
of MRI visualization and on-table adaptive radiation therapy. We
ended the second quarter with $53.9
million of cash which positions us well to execute our
business strategy. We remain on track with our guidance for 7
to 8 systems in the second half of 2017, including the recently
installed MRIdian Linac system at Henry Ford Hospital in
Michigan."
Financial Results
Total revenue for the second quarter ended June 30, 2017 was $0.7 million, compared to
$0.3 million for the same period last
year. Total revenue for the six months ended June 30, 2017 was $1.9
million, compared to $5.8
million for the same period last year. Consistent with
previous guidance, ViewRay did not recognize revenue from any new
MRIdian installations or shipments in the first half of 2017.
Cost of product revenue was $0.3
million for the second quarter ended June 30, 2017, compared to $0.1 million for the same period last year. Total
gross profit (loss) for the second quarter ended June 30, 2017 was $(0.1)
million, compared to $(0.6)
million for the same period last year. Cost of product
revenue was $0.6 million for the six
months ended June 30, 2017, compared
to $6.1 million for the same period
last year. Total gross profit (loss) for the six months ended
June 30, 2017 was $0.1 million, compared to $(1.6) million for the same period last year.
Total operating expenses for the second quarter ended
June 30, 2017 were $12.6
million, compared to $10.2 million
for the same period last year. Total operating expenses for the six
months ended June 30, 2017 were
$23.7 million, compared to
$21.2 million for the same period
last year.
Net loss for the second quarter ended June 30, 2017 was $(8.4)
million, or $(0.15) per share,
compared to $(12.1) million, or
$(0.32) per share, for the same
period last year. Net loss for the six months ended June 30, 2017 was $(36.3)
million, or $(0.67) per share,
compared to $(25.5) million, or
$(0.67) per share, for the same
period last year. The net loss in the second quarter and six months
ended June 30, 2017 included
$6.2 million of other income and
$9.1 million of other expense,
respectively, primarily from changes in the fair value of warrant
liabilities.
ViewRay had total cash and cash equivalents of $53.9 million at June 30,
2017. During the second quarter ended June 30, 2017, the Company raised $17.6 million in aggregate gross proceeds from
the sale of common stock through "at the market offerings."
Financial Guidance
The Company is reiterating its financial guidance for the full
year 2017. The Company anticipates 2017 total revenue to be in the
range of $45 million to $50 million,
primarily from the sale of 7 to 8 MRIdian Linac Systems.
Conference Call and Webcast
ViewRay will hold a conference call on Monday, August 7, 2017 at 4:30 p.m. ET / 1:30 p.m.
PT. The dial-in numbers are (844) 277-1426 for domestic
callers and (336) 525-7129 for international callers. The
conference ID number is 58602724. A live webcast of the conference
call will be available on the investor relations page of ViewRay's
corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain
available online on the investor relations page of ViewRay's
corporate website, www.viewray.com, for 90 days following the call.
In addition, a telephonic replay of the call will be available
until August 14, 2017. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. Please use the conference ID
number 58602724.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian integrates MRI
technology, radiation delivery and proprietary software to locate,
target and track the position and shape of soft-tissue tumors
during radiation. ViewRay believes this combination of enhanced
visualization and accuracy will significantly improve outcomes for
patients.
ViewRay and MRIdian are registered trademarks of ViewRay,
Inc.
Forward Looking Statements:
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, the rate of new orders, upgrades and
installations, ViewRay's financial guidance for the full year 2017
and ViewRay's conference call to discuss its second quarter 2017
financial results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize MRIdian Linac System, competition in the industry in
which ViewRay operates and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2016 and its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2017. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
VIEWRAY,
INC.
|
|
Condensed
Consolidated Statements of Operations (In thousands,
except share and per share data)
(Unaudited)
|
|
|
|
|
|
Three Months Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Gross
Orders
|
$
|
37,300
|
|
$
|
17,100
|
|
$
|
49,610
|
|
$
|
28,280
|
Backlog
|
$
|
182,119
|
|
$
|
100,740
|
|
$
|
182,119
|
|
$
|
100,740
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
5,240
|
Service
|
|
579
|
|
|
299
|
|
|
1,687
|
|
|
515
|
Distribution
Rights
|
|
119
|
|
|
—
|
|
|
238
|
|
|
—
|
Total
revenue
|
|
698
|
|
|
299
|
|
|
1,925
|
|
|
5,755
|
Cost of
revenue:
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
328
|
|
|
139
|
|
|
594
|
|
|
6,066
|
Service
|
|
498
|
|
|
724
|
|
|
1,274
|
|
|
1,325
|
Total cost of
revenue
|
|
826
|
|
|
863
|
|
|
1,868
|
|
|
7,391
|
Gross
margin
|
|
(128)
|
|
|
(564)
|
|
|
57
|
|
|
(1,636)
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
3,251
|
|
|
2,964
|
|
|
6,165
|
|
|
6,363
|
Selling and
marketing
|
|
1,871
|
|
|
1,402
|
|
|
2,943
|
|
|
2,681
|
General and
administrative
|
|
7,463
|
|
|
5,788
|
|
|
14,614
|
|
|
12,108
|
Total operating
expenses
|
|
12,585
|
|
|
10,154
|
|
|
23,722
|
|
|
21,152
|
Loss from
operations
|
|
(12,713)
|
|
|
(10,718)
|
|
|
(23,665)
|
|
|
(22,788)
|
Interest
income
|
|
1
|
|
|
—
|
|
|
2
|
|
|
1
|
Interest
expense
|
|
(1,792)
|
|
|
(1,377)
|
|
|
(3,529)
|
|
|
(2,459)
|
Other income
(expense), net
|
|
6,151
|
|
|
(20)
|
|
|
(9,122)
|
|
|
(237)
|
Loss before provision
for income taxes
|
$
|
(8,353)
|
|
$
|
(12,115)
|
|
$
|
(36,314)
|
|
$
|
(25,483)
|
Provision for income
taxes
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
Net loss
|
$
|
(8,353)
|
|
$
|
(12,115)
|
|
$
|
(36,314)
|
|
$
|
(25,483)
|
Net loss per share,
basic and diluted
|
$
|
(0.15)
|
|
$
|
(0.32)
|
|
$
|
(0.67)
|
|
$
|
(0.67)
|
Weighted-average
common shares used to compute net loss per
share
attributable to common stockholders, basic and diluted
|
|
57,230,403
|
|
|
38,234,703
|
|
|
54,540,854
|
|
|
38,223,071
|
VIEWRAY,
INC. Condensed Consolidated Balance
Sheets (In thousands, except share and per share
data)
|
|
|
June
30,
2017
|
|
December
31,
2016(1)
|
|
(Unaudited)
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
53,927
|
|
$
|
14,198
|
Accounts
receivable
|
|
1,820
|
|
|
4,200
|
Inventory
|
|
15,358
|
|
|
8,082
|
Deposits on purchased
inventory
|
|
5,516
|
|
|
2,522
|
Deferred cost of
revenue
|
|
11,163
|
|
|
3,909
|
Prepaid expenses and
other current assets
|
|
5,117
|
|
|
3,023
|
Total current
assets
|
|
92,901
|
|
|
35,934
|
Property and
equipment, net
|
|
11,388
|
|
|
11,560
|
Restricted
cash
|
|
1,143
|
|
|
1,143
|
Intangible assets,
net
|
|
87
|
|
|
97
|
Other
assets
|
|
32
|
|
|
30
|
TOTAL
ASSETS
|
$
|
105,551
|
|
$
|
48,764
|
LIABILITIES AND
STOCKHOLDERS'
DEFICIT
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
Accounts
payable
|
$
|
6,486
|
|
$
|
4,980
|
Accrued
liabilities
|
|
7,486
|
|
|
6,334
|
Customer
deposits
|
|
25,900
|
|
|
19,400
|
Deferred revenue,
current portion
|
|
13,787
|
|
|
6,515
|
Total current
liabilities
|
|
53,659
|
|
|
37,229
|
Deferred revenue, net
of current portion
|
|
3,582
|
|
|
3,918
|
Long-term
debt
|
|
44,412
|
|
|
44,290
|
Warrant
liabilities
|
|
15,128
|
|
|
2,723
|
Other long-term
liabilities
|
|
5,757
|
|
|
4,257
|
TOTAL
LIABILITIES
|
|
122,538
|
|
|
92,417
|
Commitments and
contingencies
|
|
|
|
|
|
Stockholders'
deficit:
|
|
|
|
|
|
Preferred stock, par
value $0.01 per share; 10,000,000 shares authorized at
June 30, 2017 (unaudited) and December 31, 2016; no
shares issued and outstanding
at June 30, 2017 (unaudited) and December 31, 2016
|
|
—
|
|
|
—
|
Common stock, par
value of $0.01 per share; 300,000,000 shares authorized at June 30,
2017 (unaudited) and December 31, 2017; 58,915,205
and 43,581,184 shares
issued and outstanding at June 30, 2017 (unaudited)
and December 31,
2016
|
|
579
|
|
|
426
|
Additional paid-in
capital
|
|
266,425
|
|
|
203,598
|
Accumulated
deficit
|
|
(283,991)
|
|
|
(247,677
|
TOTAL STOCKHOLDERS'
DEFICIT
|
|
(16,987)
|
|
|
(43,653
|
TOTAL LIABILITIES AND
STOCKHOLDERS' DEFICIT
|
$
|
105,551
|
|
$
|
48,764
|
|
(1) The condensed
consolidated balance sheet as of December 31, 2016 was derived from
audited financial statements as of that date.
|
View original
content:http://www.prnewswire.com/news-releases/viewray-reports-second-quarter-2017-financial-results-300500420.html
SOURCE ViewRay, Inc.